Research will focus on cancer and viral disease targets not addressable using antibody-based technologies.
Immunocore, which has developed biological drugs based on T-cell receptor (TCR) technology, has entered into a research collaboration and licensing agreement with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies, Immunocore announced in a press release today.
Under the agreement, Immunocore will be responsible for all of the preclinical development and for initial clinical trials, and GSK will be responsible for remaining development and commercialization. Immunocore will receive up to £142 million (US$212 million) in preclinical milestone payments across the targets. In addition, for each product that reaches the market, up to £200 million (US$298 million) is due to Immunocore in development and commercial milestone payments, plus up to double-digit royalties.
Immunocore’s ImmTACs (Immune mobilising mTCR Against Cancer) use TCRs to recognize intracellular changes that occur during cancer or viral infection. This unique recognition ability of TCRs sets them apart from traditional antibody-based therapies that can only recognize changes on the surface of cells, and provides the ability to develop extremely potent, targeted therapies for cancers that are currently poorly served.
Immunocore has completed development of the ImmTAC technology, including the generation of a GMP-compliant, fully scalable manufacturing route. The company has also established regulatory pathways approved by FDA and the Medicines and Healthcare products Regulatory Agency (MHRA) that will form the basis of all future ImmTAC programs. The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in Phase I/II clinical trials in the United Kingdom and United States.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.